• Emergent BioSolutions Inc., Q1 2009 Earnings Call Transcript
• Emergent BioSolutions Inc. Q4 2008 Earnings Call Transcript 06 Mar, 2009

… in continued profitability. Finally, as Fuad mentioned, we continue to pursue … upfront versus development versus procurement? Fuad El-Hibri Well, let me first … Have you gone to that? Fuad El-Hibri For competitive reasons, I …

• Emergent BioSolutions Inc. Q3 2008 Earnings Call Transcript 21 Nov, 2008

… , and our recombinant trivalent botulinum vaccine. As Fuad mentioned these development contract revenues carry with … a protest. Cory Kasimov – JPMorgan Right. Okay. Fuad El-Hibri (inaudible). Cory Kasimov – JPMorgan …

• Emergent BioSolutions Inc. Q2 2008 Earnings Call Transcript 07 Aug, 2008

… Robert Burrows – VP, Corporate Communications Fuad El-Hibri – Chairman and CEO Don … follows Following my brief introduction, Fuad will provide comments on corporate … Company And I take from Fuad’s comments that you’re …

• Emergent BioSolutions Inc. Q1 2008 Earnings Call Transcript 07 May, 2008

… Robert Burrows – VP, Corporate Communications Fuad El-Hibri – Chairman and CEO Don … the call this morning is Fuad El-Hibri, our Chairman and Chief … sales, not in the quarter-over-quarter. Fuad El-Hibri Yes, that’s absolutely …

• Emergent Biosolutions Inc. Q4 2007 Earnings Call Transcript 07 Mar, 2008

… third generation anthrax vaccine, please. Fuad El-Hibri Thank you Richard, I … military for [executive] immunization program. Fuad El-Hibri I guess the best … monopolizing on the time here. Fuad El-Hibri You’re asking some …

• Emergent Biosolutions Q3 2007 Earnings Call Transcript 02 Nov, 2007

… straightforward. Following my brief introduction, Fuad will briefly discuss third quarter … to the discounted price that Fuad indicated earlier. This discounted price … is this a new customer? Fuad El-Hibri What I can disclose …

Related posts:

1. Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011 ROCKVILLE, Md., Feb 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
2. Emergent BioSolutions to Release Fourth Quarter and Full Year 2011 Financial Results and Conduct a Conference Call on March 8, 2012 ROCKVILLE, Md.–(BUSINESS WIRE)–Jan. 30, 2012– Emergent BioSolutions Inc. (NYSE: EBS)...
3. Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions...

Related posts brought to you by Yet Another Related Posts Plugin.

Emergent BioSolutions Inc. today announced the appointment of Allen Shofe to the position of Vice President of Government Affairs. Fuad El-Hibri appoints Allen Shofe Vice President of Government Affairs

Emergent BioSolutions Appoints Allen Shofe Vice President of Government Affairs

GAITHERSBURG, Md., Sept. 15 /PRNewswire/ — Emergent BioSolutions Inc. today announced the appointment of Allen Shofe to the position of Vice President of Government Affairs.  In this position, Mr. Shofe will be responsible for designing, implementing and overseeing all aspects of the company’s domestic and international government affairs initiatives.

“Allen is a versatile and highly astute government relations and public affairs executive,” said Fuad El-Hibri, CEO of Emergent BioSolutions.  “His government affairs expertise and extensive network of professional contacts throughout the United States and Europe will prove invaluable as we continue our efforts to become a global leader in our field.”

Mr. Shofe has more than 15 years experience in government relations and government affairs at the Federal and state levels, as well as in the international arena.  Mr. Shofe previously held the position of Director of Federal Government Relations at Eli Lilly and Company, where he managed a series of government initiatives, including those that focused on intellectual property, patent law and tort reform.  Mr. Shofe received his BA in International Relations/Diplomacy at the University of Minnesota and an LL.M, Master of Laws from the University of Leicester in the United Kingdom. “I look forward to the opportunity to help advance Emergent BioSolutions into a world class biopharmaceutical company,” said Mr. Shofe.  “This company has such a promising future, and to be a part of its growth and success is something I am extremely proud of.”

About Emergent BioSolutions
Emergent BioSolutions Inc., formed in 2004, is dedicated to the research, development and manufacture of novel products which harness the immune system to treat and prevent disease.  These include vaccines and related products for prophylactic and therapeutic use against common infectious diseases and biological weapons of mass destruction.  The company currently employs more than 450 people with facilities in Gaithersburg and Frederick, Maryland, Lansing, Michigan, Berkshire, U.K. and Munich Germany.  More information about Emergent BioSolutions and its subsidiaries can be found at http://www.ebsi.com

Posted in Allen Shofe, El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri
Tags: Eli Lilly and Company, Emergent BioSolutions, Maryland, Politics, United States, University of Leicester, University of Minnesota, Weapon of mass destruction

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.